Cargando…
A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice
AIMS: To assess effects of DF402, a bioisostere of Dimebon/Latrepirdine, on the disease progression in the transgenic model of amyotrophic lateral sclerosis (ALS) caused by expression of pathogenic truncated form of human FUS protein. METHODS: Mice received DF402 from the age of 42 days and the onse...
Autores principales: | Chaprov, Kirill, Rezvykh, Alexander, Funikov, Sergei, Ivanova, Tamara A., Lysikova, Ekaterina A., Deykin, Alexei V., Kukharsky, Michail S., Yu. Aksinenko, Alexey, Bachurin, Sergey O., Ninkina, Natalia, Buchman, Vladimir L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193697/ https://www.ncbi.nlm.nih.gov/pubmed/33754495 http://dx.doi.org/10.1111/cns.13637 |
Ejemplares similares
-
Dimebon Slows Progression of Proteinopathy in γ-Synuclein Transgenic Mice
por: Bachurin, Sergey O., et al.
Publicado: (2011) -
Differences in bioavailability and cognitive-enhancing activity exerted by different crystal polymorphs of latrepirdine (Dimebon(®))
por: Gorin, Boris I., et al.
Publicado: (2023) -
Stem cells in human breast milk
por: Ninkina, Natalia, et al.
Publicado: (2019) -
Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease
por: Eckert, Schamim H, et al.
Publicado: (2018) -
Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo
por: Steele, John W, et al.
Publicado: (2009)